News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
607,846 Results
Type
Article (49094)
Company Profile (198)
Press Release (558554)
Section
Business (170544)
Career Advice (1976)
Deals (30288)
Drug Delivery (84)
Drug Development (75086)
Employer Resources (148)
FDA (16134)
Job Trends (13631)
News (298580)
Policy (29758)
Tag
Academia (2704)
Africa (779)
Alliances (44489)
Alzheimer's disease (1124)
Approvals (16057)
Arizona (150)
Artificial intelligence (72)
Asia (36679)
Australia (6268)
Bankruptcy (254)
Best Places to Work (10674)
Biotechnology (133)
Breast cancer (54)
C2C Services and Suppliers (77502)
California (1663)
Canada (842)
Cancer (515)
Career advice (1655)
Cell therapy (131)
China (148)
Clinical research (59006)
Collaboration (143)
Colorado (72)
Connecticut (66)
COVID-19 (2536)
Cystic fibrosis (73)
Data (306)
Diabetes (78)
Diagnostics (5627)
Drug pricing (66)
Earnings (61842)
Employer resources (131)
Europe (81770)
Events (85870)
Executive appointments (144)
FDA (16365)
Florida (255)
Funding (149)
Gene therapy (91)
Georgia (56)
GLP-1 (533)
Government (4346)
Healthcare (18403)
Hotbed/Location (403267)
Illinois (252)
Indiana (146)
Infectious disease (2561)
Inflammatory bowel disease (101)
Interviews (324)
IPO (13802)
Job creations (3089)
Job search strategy (1430)
Kansas (84)
Layoffs (344)
Legal (6169)
Liver cancer (57)
Lung cancer (121)
Manufacturing (86)
Maryland (384)
Massachusetts (1313)
Medical device (13935)
Medtech (13939)
Mergers & acquisitions (16417)
Metabolic disorders (261)
Michigan (107)
Minnesota (179)
Neuroscience (1274)
New Jersey (529)
New York (548)
NextGen Class of 2024 (6504)
Non-profit (4469)
North Carolina (575)
Northern California (755)
Obesity (162)
Ohio (93)
Opinion (208)
Patents (67)
Pennsylvania (506)
People (49745)
Phase I (17772)
Phase II (26101)
Phase III (19975)
Pipeline (109)
Postmarket research (2363)
Preclinical (7208)
Press Release (61)
Rare diseases (135)
Real estate (5090)
Recruiting (58)
Regulatory (20190)
Research institute (2423)
Resumes & cover letters (313)
South America (1071)
Southern California (677)
Startups (3656)
Texas (217)
United States (7730)
Vaccines (495)
Washington State (218)
Weight loss (150)
Date
Today (100)
Last 7 days (629)
Last 30 days (2231)
Last 365 days (34871)
2024 (24410)
2023 (37478)
2022 (48285)
2021 (52260)
2020 (51144)
2019 (44966)
2018 (34181)
2017 (31038)
2016 (30044)
2015 (34811)
2014 (26682)
2013 (22282)
2012 (23937)
2011 (24526)
2010 (22490)
607,846 Results for "ra medical systems".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Drug Development
Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA).
June 17, 2024
·
7 min read
Business
Ra Medical Systems Announces First Quarter 2023 Results
Ra Medical Systems, Inc. announced financial and company highlights for the first quarter ended March 31,2023.
June 2, 2023
·
12 min read
Drug Development
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.
April 8, 2024
·
8 min read
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. announced the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement.
April 30, 2024
·
5 min read
Press Releases
SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
July 10, 2024
·
5 min read
Drug Development
Sysmex Inostics’ RAS-RAF-SEQ Assay Receives New York State Department of Health CLEP Approval for Use in Clinical Trials
September 17, 2024
·
3 min read
Deals
Ra Medical Systems Completes Merger with Catheter Precision
Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces the completion of its previously announced stock-for-stock merger transaction with Catheter Precision, Inc., a company focused on the cardiac electrophysiology market.
January 9, 2023
·
10 min read
Ra Medical Systems Announces Date of Special Shareholder Meeting
Ra Medical Systems (NYSE American:RMED) today announced the date of March 21, 2023 as the date of its special shareholder meeting.
February 10, 2023
·
1 min read
Biotech Beach
Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
April 10, 2024
·
3 min read
1 of 60,785
Next
